Hologic, Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 4,704 shares of the business’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $45.19, for a total transaction of $212,573.76. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Hologic, Inc. (NASDAQ HOLX) traded up 0.39% during midday trading on Monday, reaching $44.29. 1,040,583 shares of the company’s stock traded hands. The company’s 50-day moving average price is $45.08 and its 200 day moving average price is $42.89. The stock has a market capitalization of $12.40 billion, a price-to-earnings ratio of 15.88 and a beta of 0.91. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.04. The business had revenue of $715.40 million for the quarter, compared to the consensus estimate of $685.24 million. Hologic had a net margin of 27.31% and a return on equity of 25.26%. Hologic’s quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the company posted $0.47 earnings per share. On average, equities research analysts expect that Hologic, Inc. will post $2.01 earnings per share for the current year.
WARNING: “Karleen Marie Oberton Sells 4,704 Shares of Hologic, Inc. (HOLX) Stock” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://stocknewstimes.com/2017/07/31/karleen-marie-oberton-sells-4704-shares-of-hologic-inc-holx-stock-updated.html.
Several large investors have recently made changes to their positions in the company. Lincoln Capital Corp bought a new stake in shares of Hologic during the fourth quarter valued at about $377,000. UBS Asset Management Americas Inc. increased its stake in shares of Hologic by 123.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,446,445 shares of the medical equipment provider’s stock valued at $58,032,000 after buying an additional 798,541 shares during the last quarter. Whalerock Point Partners LLC increased its stake in shares of Hologic by 57.4% in the fourth quarter. Whalerock Point Partners LLC now owns 37,850 shares of the medical equipment provider’s stock valued at $1,519,000 after buying an additional 13,800 shares during the last quarter. Teachers Advisors LLC increased its stake in Hologic by 28.8% in the fourth quarter. Teachers Advisors LLC now owns 643,547 shares of the medical equipment provider’s stock worth $25,819,000 after buying an additional 143,960 shares in the last quarter. Finally, Kentucky Retirement Systems acquired a new stake in Hologic during the fourth quarter worth $810,000. Institutional investors and hedge funds own 94.32% of the company’s stock.
HOLX has been the topic of several recent research reports. Needham & Company LLC upped their price target on shares of Hologic from $46.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, April 4th. Zacks Investment Research raised shares of Hologic from a “sell” rating to a “strong-buy” rating and set a $49.00 price target on the stock in a report on Tuesday, April 4th. Barclays PLC set a $50.00 price target on shares of Hologic and gave the company a “buy” rating in a report on Wednesday, April 5th. Canaccord Genuity reaffirmed a “buy” rating and issued a $53.00 price target on shares of Hologic in a report on Tuesday, May 9th. Finally, Stifel Nicolaus upped their price target on shares of Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $48.38.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
